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S_nminary Photodynamic therapy (PDT) is an experimental approach to the treatment of neoplasms in which
photosensitisers (PSs) accumulated in malignant tissues are photoactivated with appropriate wavelengths of
light. The target specificity of PSs may be improved by linking them with carrier macromokcules such as
monoclonal antibodies (MAbs). OC125 is a murine MAb that recognises the antigen CA 125, which is
expressed on 80% of non-mucinous ovarian tumours. A chlorin derivative conjugated to OC125 was shown to
be selectively phototoxic to ovarian cancer and other CA 125-positive cells in vitro and ex vivo. We now report
in vivo studies using an ascitic Balb c nude mouse ovanran cancer model. Ascites was induced by intra-
peritoneal injection of cells from the human ovarian cancer cell line NIH:OVCAR3. Six weeks after injection,
when the animals had developed ascites. biodistribution studies were carried out by injecting the immunocon-
jugate (IC) or free PS intraperitoneally and sacrificing the animals at 3, 6. 12. 24, 48, 72 and 168 h later. The
PS was quantitated by extraction and fluorescence spectroscopy. For both the IC and free PS. peak tumour
concentrations were reached at 24 h; however, the absolute concentrations for the IC were always higher (2- to
3-fold) than the free PS. Tumour to non-tumour ratios at 24 h for the IC were 6.8 for blood. 6.5 for liver, 7.2
for kidney. 5.7 for skin and 3.5 for intestine. Evaluation of viable tumour cells in ascites following in vivo PDT
with a single light exposure demonstrated a dose-dependent relationship with fluence and IC concentration.
However, there was significant treatment-related toxicity at all fluences. With multiple low-dose treatments, the
percentage of viable tumour cells was also significantly reduced and there were no treatment-related deaths.
These data suggest that, while photoimmunotherapy remains promising as a new treatment modality for
ovanan cancers, careful quantitative dosimetry of both IC and light may need to be combined with multiple
treatments (as with radiation therapy and chemotherapy) to control malignant disease yet maintain acceptable
toxicity in vivo.
Ovarian cancer is the second most common gynaecological
malignancy in Western women, and it is currently the fourth
leading cause of cancer death (Boring et al., 1993). It is a
disease that is largely localised to the peritoneal cavity and,
therefore, may be amenable to localised therapies which have
tumour cell selectivity such as photodynamic therapy (PDT).
PDT is an experimental approach to the treatment of neo-
plasms which may alleviate some of the problems associated
with the lack of specificity ofconventional therapies and may
be particularly appropriate in the treatment of ovanran cancer
because of the generally localised nature of the disease. In
PDT, non-toxic photoactivatable compounds, photosensi-
tisers, are accumulated in normal and malignant tissues
(Dougherty, 1987). Exposure to the appropriate wavelength
of light causes phototoxicity by the production of cytotoxic
species, such as singlet oxygen (Weishaupt, 1976). PDT pro-
vides some increased selectivity by a combination of
photosensitiser localisation to the tumour and the spatial
control of illuminated areas. In principle, this should
minimise toxicities to normal tissues.
Currently, the majority of clinical applications use
haematoporphyrin derivative (HPD), a mixture of porphy-
rins, the relatively more purified form of which is Photofrin
(PF). Reasonable success without side-effects such as pro-
longed skin phototoxicity using PF or HPD has been
obtained in only a few clinical situations (Marcus, 1992). Of
particular interest and relevant to ovarian cancer is a study
by Tochner et al. (1985, 1986) in the treatment of murine
intraperitoneal ovarian acities tumour with HPD and 514 nm
irradiation. These investigators showed effective ascitic
photodestruction in 17 of 20 animals with four treatments of
HPD using intraperitoneal irradiation. These results prompt-
ed human phase I PDT studies using PF in the treatment of
disseminated intraperitoneal malignancies (Delaney et al.,
1993). During these trials, in addition to the cutaneous
phototoxicity, which could persist for up to 60 days, small
bowel perforations developed at anastomotic sites. These
problems were attributed to non-specific localisation of the
photosensitiser, and have stimulated the search for
new photosensitisers with improved specificity (Gomer
1991).
An alternative way to improve target specificity of
phototoxic compounds is to link them with carrier molecules
such as monoclonal antibodies (Mew et al., 1983, 1985;
Oseroff et al., 1986; Hasan et al., 1989a-c; Jiang et al., 1990;
Rakestraw et al., 1990). One of the main problems associated
with the use of antibodies is their large size and high
reticuloendothelial system (RES) capture. In addition to
systemic toxicity, this process greatly reduces the antibody
available to the target. Intracavity administration ofantibody
or conjugates in the target region reduces such RES capture
in the first pass post administration and is possibly the more
realistic application of antibody conjugates. We have,
therefore, initiated a programme aimed at photochemical
targeting of ovarian cancer cells using monoclonal anti-
body-photosensitiser conjugates administered intra-
peritoneally. The photosensitiser chlorin e6 monoethylendi-
amine monamide (CMA) was conjugated site specifically via
polyglutamic acid (PGA) to a murine monoclonal antibody,
OC125 (Goff et al., 1991). OC125 recognises the antigen CA
125 (Bast et al., 1981), which is expressed on 80% of non-
mucinous ovarian cancers (Bast et al., 1981; Davis et al.,
1986; Miotti et al., 1987). The conjugate was significantly
more phototoxic to ovarian cancer cells both in vitro (cell
lines) and ex vivo (from cancer patients) (Goff et al., 1991,
1992), while exhibiting no phototoxicity to CA 125-negative
cells.
The present study is an extension of our previous in vitro
and ex vivo photodynamic experiments and reports the re-
sults of our initial in vivo investigations. As a first step in this
direction, we investigated the biodistribution and tumour
uptake of the OC125-IC in a murine ascites ovarian cancer
model by photosensitiser extraction and fluorescence spectro-
Correspondence: T. Hasan. Massachusetts General Hospital. Well-
man Laboratories of Photomedicine, WEL 224. 55 Fruit Street.
Boston, MA 02114, USA.
Received 28 September 1993: and in revised form 7 January
1994.
Br. J. Cancer (1994), 70, 474-480 (C) Macmillan Press Ltd., 1994PDT WITH AN OC125 IMMUNOCONJUGATE 475
scopy. Preliminary studies evaluating the effectiveness of
PDT using this conjugate were also conducted in the same
model.
Materials and metods
Twnour cells
NIH:OVCAR3 cells were a generous gift from Centocor
(Malvern, PA, USA). This cell line was derived from the
ascites of a patient with ovarian cancer (Hamilton et al.,
1983). Cells were grown in RPMI-1640 medium supple-
mented with heat-inactivated fetal bovine serum and kept in
an incubator at 37C in an atmosphere of 5% carbon diox-
ide. For tumour transplantation, cells were trypsinised (tryp-
sin-EDTA, Gibco, Grand Island, NY, USA), centrifuged at
1,000 r.p.m. for 10 min (model 6000B, Sorvall Centrifuges,
Dupont, Wilmington, DE, USA) and resuspended in 1 ml of
phosphate-buffered saline (PBS) (Gibco) for intraperitoneal
injection.
Tumour model
Experiments were carried out in a murine model for ovarian
cancer developed by Hamilton et al. (1984). Balb/c athymic
nude mice (Charles River Breeding Laboratories) were given
intraperitoneal injections of 30 x 106 NIH:OVCAR3 cells.
This results in the development of serosal metastases similar
to that of ovarian cancer in humans. Disease progression is
characterised by the development of massive ascites and
extensive intraperitoneal tumours. Within 6 weeks, animals
develop clinical evidence of ascites, at which time biodistribu-
tion studies are performed.
Photosensitisers
CMA was obtained from Porphyrin Products (Logan, UT,
USA) and the PGA was obtained from Sigma (St Louis,
MO, USA). The monoclonal antibody OC125 was a gift
from Centocor, and was coupled site specifically at its
carbohydrate moiety with CMA-bound PGA as previously
described to form the OC125-PGA-CMA IC (Goff et al.,
1991).
PhotodXna,mic treatment in vivo
Mice were injected with 30 million NIH:OVCAR3 cells.
Seven days after injection, animals were given an intra-
peritoneal injection of IC or CMA (at 0.5 and 2.0 mgkg-'
CMA equivalent as described above) followed by irradiation
24 h later. Controls were injected with sterile PBS. Animals
in one group (PS dose 2.0mg kg-') were immobilised and
given external whole-abdomen irradiation (field size approxi-
mately 3.5 cm diameter) with an argon ion pumped dye laser
(Coherent, Palo Alto, CA, USA) at a wavelength of 656 nm
(i,, for CMA). External irradiation was used in these initial
studies because there was no requirement for sedation or
violation of the peritoneal cavity. Also, in nude mice, the
abdominal wall is thin (<2 mm) and presents minimal bar-
rier to 656 nm irradiation (Svaasand et al., 1990). The power
density measured at the skin surface was 40-70 mWcm2,
and the fluence administered was 20 and 30 J cm-2. The
second group (PS dose 0.5 mg kg-') was sedated with sodium
pentabarbital and intraperitoneal irradiation was carried out
according to the method of Tochner et al. (1985, 1986) at
656 nm, 50 mW and 1 min per quadrant. Animals were
treated with PS and light every 48 h for a total of three
treatments. A quantitative assessment of the extent of
ovarian cancer cell destruction was performed ex vivo for
both groups of animals. One hour after irradiation the ascites
was harvested with a 15 gauge needle. RBCs were lysed with
0.83% amonium chloride (Aldrich Chemical, Milwaukee,
WI, USA). Ovarian cancer cells were washed in sterile
Dulbecco's PBS (Gibco, Grand Island, NY, USA) and
placed in 35 mm Petri dishes at a concentration of
150,000 cells ml' in RPMI-1640 medium (Gibco) containing
10% fetal bovine serum. Forty-eight hours after plating, the
survival of treated and control ex vivo cultures was determined
by the 3-(4,5-dimethylthiazol-2-yl)-2,5 diphenyl terazolium
bromide (MTT) colorimetric assay (Mosmann, 1983).
Results
Photosensitisers
The qualitative UV-visible absorption spectra for free CMA
and the OC125-PGA-CMA (IC) are shown in Figure 1. The
spectra are essentially similar, though the IC shows a 3-5 nm
blue shift compared with free CMA.
Biodistribution
CMA was injected intraperitoneally at a dose of
2.0 mg per kg body weight; the IC and PGA-CMA were
injected at CMA equivalents matched for identical absorp-
tion at 656 nm with the free CMA solution. Following injec-
tion of the photosensitiser, animals (n = 5-7) were sacrificed
by cervical dislocation at 3, 6, 12, 24, 48, 76 and 168 h. The
ascites containing tumour cells, kidney, liver, skin, small
intestine and plasma were harvested from the animals. For
the intestine specimen, the whole wall including mucosa,
submucosa, muscle and serosa was sampled. Wet tissue
samples were weighed and frozen at - 70C. For extraction
of the photosensitiser the samples were homogenised
(homogeniser model PT 10/35, Brinkman Instruments, West-
bury, NY, USA) in 3 ml of 0.1 M sodium hydroxide and
centrifuged at 17,000 r.p.m. (Sorvall RC-5B, refrigerated
superspeed centrifuge, Dupont Instruments) for 20 min
(Bachor et al., 1992). The fluorescence of the supernatant was
measured with a spectrofluorimeter (Fluorolog 2, Spex Indus-
tries, Edison, NJ, USA) and compared with that of a standard
solution of CMA, PGA-CMA or OC125-PGA-CMA (IC).
The excitation wavelength was 400 nm and emission spectra
were monitored between 500 and 700 nm. The fluorescence of
tissue samples from untreated animals was used for back-
ground correction. The quantitative nature of the extraction
procedure was established by spectrophotometric readings of
successive extracts and by comparison with extracts of
known mixes of PSs and tissues.
Biodistribution
The tumour content of CMA, PGA-CMA and IC as a
function of time are shown in Figure 2. The peak concentra-
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Figue 1 IJ-visible absorption spectra of CMA and IC dis-
solved in PBS. The CMA concentration was 7.1 iM in PBS and
the IC concentration was arbitrarily adjusted to display the spect-
rum clearly.
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tion for CMA occurs at 24 h and slowly declines over time.
The tissue distribution of free CMA is shown in Table I. For
blood, there is a brief peak at 6 h, following which the level
drops to almost zero. For liver and kidney there is almost no
uptake of CMA. In the skin and intestines there is some
uptake initially at 3, 6 and 12 h, but the tissue concentrations
drop off by 24 h.
The biodistribution of PGA-CMA is shown in TaJle II.
Peak tumour tissue concentrations of PGA-CMA are found
at 3 h and slowly decline over time. As for other tissues,
blood, liver and kidney have minimal uptake. However, skin
and intestine retain significant amounts of PGA-CMA and
have tissue concentrations similar to tumour levels. The
tumour to skin and intestine ratios were in general close to 1
at most time points. At 3 and 24 h, tumour to skin ratios of
up to 3 were obtained. At these time points, the tumour to
intestine ratios were 1.6 and 0.8 respectively.
The tissue distribution of the IC is shown in Table III. The
peak tumour concentration (3.18 ± 1.38 nmol per g of tissue)
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Fiwe 2 Balb'c nude mice with ovarian ascites tumours were
injected intraperitoneally with 2.0 mg kg-' CMA (0), PGA-
CMA (0) or IC (A) (for PGA-CMA and IC, CMA equivalently
matched by absorption at 656 nm). The curves represent the
tumour content of each compound in nmol g-' tissue over
time.
also occurs at 24 h, as with CMA (Figure 2); however, the
mean tissue concentration of the IC is twice that of free
CMA. As levels decline in the tumour, liver and kidney
concentrations increase, with peak tissue concentration of IC
occurring at 168h in these tissues (1.03 ±0.34nmolg-' for
liver and 0.69 ± 0.35 for kidney). Blood concentrations are
low at all time points. The levels in the intestine are modestly
elevated and peak at 12 h. At 24 h, the concentration of IC
in tumour is 3.5 times greater than in the intestines, but IC
remains in the intestines even at 336 h.
Tumour to non-tumour ratios for free CMA, PGA-CMA
and IC are presented in Table IV for all measured time
points and in Figure 3 for the 3, 12 and 24 h time points. For
the IC, the peak tumour concentration (3.18 ± 1.38 nmol g-'
tissue) occurs at 24 h. At that time, tumour to non-tumour
ratios are 6.8 for blood, 6.5 for liver, 7.2 for kidney, 5.7 for
skin and 3.5 for intestine. At 48 and 72 h tumour to non-
tumour ratios decrease for all tissues except blood; however,
the ratios are all still above 2. For CMA, tissue concentra-
tions are generally about half those for IC; peak tumour
concentrations (1.67 ± 0.40 nmol g-' tissue) occur at 24 h, as
with the IC. Tumour to non-tumour ratios appear to be
high. However, the lower absolute concentrations border the
detection limits.
Photodynamic therap)
Once the biodistribution studies had identified 24 h following
injection of CMA or IC as an appropriate starting time for
irradiation, in vivo-in vitro experiments were carried out to
assess the extent of photodynamic destruction of the ascites
tumour cell population. Ascites harvested from tumour-
bearing animals after treatment with IC or CMA and light
was assayed for survival by the MTI assay and compared
with untreated controls. The results are presented in Table V.
Animals were initially treated with a single external light
exposure. At a dose of 2 mg kg-' and 20 J cm-2 40% of the
cells treated with the IC and 70% of cells treated with CMA
survived. At 30 J cm-2, cell survival was 14% and 56% for
IC and CMA treatment respectively. However, even at the
lower light dose, 30-50% of the animals treated with IC or
with CMA died secondary to treatment toxicity. Histological
profiles of dead animals 24 h post PDT showed vascular
congestion in liver, kidney, lung and spleen similar to those
Table I Mean concentrations (mnol g' tissue) of free CMA in mice (± s.d.)
Time
(h) Ascites Blood Liver Kidne) Skin Intestine
3 0.91 ± 0.37 0.18 ± 0.16 0.07 ± 0.04 0.04 ± 0.03 0.31 ± 0.27 0.54 ± 0.78
6 1.39 0.73 0.43 0.05 0.08 ± 0.05 0.06 ± 0.04 0.32 ± 0.19 0.37 ± 0.17
12 1.28 0.79 0.01 ±0.007 0.07 ± 0.05 0.03 ± 0.03 0.21 ± 0.13 0.12 ± 0.12
24 1.67±0.40 0.02±0.02 0.06±0.04 0.03±0.03 0.09±0.05 0.11 ±0.12
48 1.50±0.86 0.01 ±0.01 0.05±0.03 0.02±0.02 0.06±0.05 0.07±0.08
72 1.12 ± 0.34 0.005 ± 0.005 0.03 ± 0.02 0.02 ± 0.02 0.06 ± 0.04 0
'Balblc nude mice (n = 5-7) with ovarian ascites tumours were injected intraperitoneally with 2 mgkg-'
CMA. Animals were sacrificed at various times. The amount of CMA was quantitated by extraction followed
by fluorescence spectroscopy.
Table n Mean concentrations (nmol g' tissue) of PGA-CMA in mice' (± s.d.)
Time
(h) Ascites Blood Liver Kidne- Skin Intestine
3 3.91 ±2.51 0.55 0.58 0.55 0.03 0.30 0.46 1.45 0.37 2.46 0.38
6 2.44 ± 0.33 0.67 ± 0.3 0.65 ± 0.46 0.23 ± 0.32 2.88 ± 1.45 2.44 ± 2.45
12 2.42 1.42 0.14 0.10 1.08 0.63 0.47 0.41 3.32 1.02 1.14 0.44
24 2.18 0.39 0.28 0.05 0.46 0.13 0.24 0.26 1.30 0.78 2.75 0.24
48 1.22 0.29 0.20 0.12 0.60 0.15 0.14 0.25 1.25 ±0.11 0.91 ±0.53
72 1.34 ± 0.05 0.46 ± 0.044 0.42 ± 0.10 0.13 ± 0.12 1.87 ± 0.42 1.93 ± 1.06
168 0.51±0.10 0.16±0.09 0.32±0.10 0.09±0.16 1.10±1.07 2.78±1.56
'Balb/c nude mice (n =5-7) with ovarian ascites tumours were injected intraperitoneally with 2mg kg-'
PGA-CMA (CMA equivalent determined by matching 656nm aborbance to a standard CMA solution).
Animals were sacrificed at various times. The amount of PGA-CMA was quantitated by extraction followed
by fluorescence spectroscopy.
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Tal M Mean concentrations (nmol g-' tissue) of IC in mice5 (± s.d.)
Time
(h) Ascites Blood Liver Kidney Skin Intestine
3 2.84 ± 2.07 0.36 ± 0.25 0.43 ± 0.29 0.35 ± 0.25 0.31 ± 0.30 1.34 ± 1.03
6 2.58 ± 1.99 0.34 ± 0.26 0.47 ± 0.34 0.27 ± 0.14 0.69 ± 0.39 0.86 ± 0.60
12 2.36 ± 1.16 0.40 ± 0.36 0.47 ± 0.26 0.57 ± 0.28 0.59 0.26 2.14 1.04
24 3.18± 1.38 0.47±0.19 0.49±0.16 0.44±0.30 0.56±0.23 0.92±0.44
48 2.25± 1.10 0.19±0.11 0.74±0.48 0.50±0.28 1.03±0.27 0.91 0.62
72 2.21 ±0.55 0.14±0.09 0.46±0.32 0.48±0.30 0.58 0.37 1.11 0.95
168 0.80 ± 0.45 0.04± 0.05 1.03 ± 0.34 0.69 ± 0.35 0.95 0.17 1.30 0.45
336 0.32 0.13 ± 0.01 0.70 ± 0.19 0.32 ± 0.04 0.31 ± 0.18 0.91 ± 0.70
aBalb,c nude mice (n = 5-7) with ovarian ascites tumours were injected intraperitoneally with 2 mgkg-' IC
(OC125-PGA-CMA at CMA equivalent determined by aborbance matching at 656 nm). Animals were
sacrificed at various times. The amount of IC was quantitated by extraction followed by fluorescence
spectroscopy.
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Fugwe 3 Biodistribution of PGA-CMA (_, skin; W,
intestine) and IC ( V, skin; intestine) 3, 12 and 24 h after
intraperitoneal administration. Data are presented as tumour to
skin and tumour to intestine ratios.
described by Ferrario and Gomer (1990). Because of the
toxicity experienced by these animals, the IC and CMA dose
was lowered to 0.5 mgkg-' and intraperitoneal irradiations
were carried out at doses of approximately 5 Jcm-2 per
treatment for a total of 15 J CM-2. Following three such PDT
treatments (of both PS and light) the fraction of viable
tumour cells in the ascites of the animals treated with IC was
approximately 5% of control. For those treated with free
CMA the viable tumour cells were 15% of control. Under
these conditions, no toxicity to animals was noted.
Discussio
Monoclonal antibody immunoconjugates are being investi-
gated for use in tumour localisation and treatment in a
variety of malignant diseases. Indium-l 11-labelled OC125 has
been used for tumour localisation in ovarian cancer patients
(Chatal et al., 1989). Doxorubicin linked to OC125 has
shown improved cytotoxicity in vitro against an ovarian
cancer cell line compared with unconjugated doxorubicin
(Sweet et al., 1989). Because ovarian cancer is usually limited
to the peritoneal cavity, intraperitoneal injections of ICs may
be the preferred route of administration, as demonstrated by
several previous studies (Ward & Wallace, 1987; Ward et al.,
1987; Ward & Piko, 1987). Indeed, with radioimmunocon-
jugates intraperitoneal injection results in higher tumour
uptake, presumably because of the greater ability of IC to
access its tumour antigenic target (Ward et al., 1987; Finkler
et al., 1989; Thedrez et al., 1989) prior to RES capture. With
intravenous injection of "'In-OC125 in an ascitic murine
Table IV Tumour to non-tumour ratios'
Tiue
(h) Blood Liver Kidney Skin Intestine
C.A
3 5.0 13.0 22.7 2.9 1.7
6 3.2 17.4 23.2 4.3 3.8
12 128.0 18.3 42.7 6.1 10.7
24 83.5 27.8 55.7 18.5 15.2
48 150.0 30.0 75.0 25.0 21.4
72 224.0 37.3 56.0 18.7 -
PGA-CMA
3 7.1 7.1 11.1 2.7 1.6
6 3.6 3.7 10.6 0.8 1.0
12 17.3 2.2 5.1 0.7 2.1
24 7.8 4.7 9.0 3.0 0.8
48 6.1 2.0 8.7 1.0 1.3
72 5.7 5.8 18.7 1.3 1.3
168 3.1 1.6 5.6 0.5 0.2
OC125-PGA-CMA
3 7.9 6.6 8.1 9.2 2.1
6 7.6 5.5 9.5 3.7 3.0
12 5.9 5.0 4.1 4.0 1.1
24 6.8 6.5 7.2 5.7 3.5
48 11.8 3.0 4.5 2.2 2.5
72 15.8 4.8 4.6 3.8 2.0
168 20.0 0.8 1.2 0.8 0.7
336 2.5 0.4 1.0 1.0 0.4
'Numbers represent the ratio of CMA, PGA-CMA, or
OC125-PGA-CMA (IC) in ascites tumour cells compared with
normal tissue.
Table V In vivo-in vitro experiments with ascites-beanrng mice'
( s.d.)
IC CMA
2mgkg-'-20Jcm-' 40.3± 14.9 71.7± 4.8
2 mgkg-'-30 J cm-2 14.1 ± 10.1 56.5 ± 24.3
0.5mgkg-'- 5 Jcm-2i.p. 5±1.5 15± 5.9
'Numbers represent percentage of cells which survived as deter-
mined by MTr assay as compared with untreated controls. Animals
administered 2 mgkg-' PS were irradiated externally. Animals
treated with 0.5 mg kg-' PS were irradiated intraperitoneally. In
each group there were 7-10 animals.
model similar to the one used in this study, uptake in tumour
was significantly lower than after administration by the intra-
peritoneal route, while the RES uptake was high. Tumour to
non-tumour ratios were also reported to be significantly
lower after intravenous injection and the amount of the
radioisotopic antibody in normal tissue, in particular the
organs of the RES, was high, with consequent toxicity
(Thedrez et al., 1989). Based on such rationale, radioim-
munotherapy using intraperitoneally injected "'I-labelled
OC125 has been studied in phase I trials to treat recurrent
ovarian carcinoma (Finkler et al., 1989; Muto et al., 1992).
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Toxicity was minimal, but tumour progression was noted in
the majonty of patients and no complete responses were
obtained. For ligand doses which are curative or inhibit
tumour progression, systemic toxicty from bound toxins or
radioisotopes remains a significant problem because of the
lack of specificity of most monoclonal antibodies. Clearly,
other modes of treatments are required for effective and less
toxic cure or palliation of ovarian cancer.
Using monoclonal antibodies to deliver photosenstisers
seectively is a relatively recent treatment approach that has a
potential for minimnising normal tissue toxicity from anti-
body-bound toxic ligands. Since the first such study by Mew
et al. (1983), the approach has been further developed
(Hasan et al., 1989a-c, 1992, 1993; Jiang et al., 1992, 1993).
However, reports of in vivo examination of this approach
have been limited (Mew et al., 1983; Hasan et al., 1989a;
Jiang et al., 1993). In the present study we characterise the
biodistribution and toxicity of this IC in a murine ovarian
cancer model that has many similarities to the clinical course
of ovarian cancer in humans.
The tumour to non-tumour ratio may determine the opti-
mal time for treatment. Ideally, there should be high
photosensitiser concentration in tumours with low concentra-
tions in surrounding normal tissues. Although the photosen-
sitser concentrations for the PGA-CMA and the IC were
imilar, the tumour to non-tumour ratios for skin and intes-
tine for PGA-CMA are close to unity at several time points
(Figure 3). At points when tumour-skin ratios of close to 3
were obtained for PGA-CMA, the tumour-intestine ratios
were low (1.6 and 0.8 at 3 and 24h respectively). Since the
phase I trials with HiPD suggested bowel perforation as a
major complication, this compound seemed unattractive for
treatment because of increased risk of toxicity to these
organs. For the IC the highest tumour to non-tumour ratios
occurred at 24-48 h. These ratios are similar to what other
investigators have found for radiolabelEd OC125 (Thedrez et
al., 1989). Apparently linking CMA to OC125 does not
significntly affect the binding of the monoclonal antibody in
vivo. The unexpected result from this study was the apparent
very high tumour to non-tumour ratios seen with free CMA
at 24, 48 and 72 h.
Despite the apparent high tumour to non-tumour ratios
for free CMA (lI0-fold), CMA was significantly less photo-
toxic to ovarian cancer cells in vivo. Tumour cell survival
after in vivo treatment with identical doses of IC or CMA
and light indicates that the percentage oftumour cells surviv-
ing after IC treatment is 2- to 4-fold less than with the free
CMA (Table V). This reduced cytotoxicity of CMA to
tumour cells could be caused by the smaller absolute CMA
concentrations in tumour cells or possibly by the presence of
a non-photoactive metabolite of CMA with similar spectral
properties. For another chlorin derivative, mono-L-aspartyl-
chlorin e6, Gomer and Ferrario (1990) found that the tumour
concentration and tumour to non-tumour ratios were also
not predictive of optimal treatment times and toxicity. In
their murine model of subcutaneous mammary cancer, the
most significnt tumour necrosis occurred when plasma levels
of the chlorin derivative were high, suggesting vascular-
mediated damage as the primary target. Since ovarian cancer
is a diseas that spreads superfially along peritoneal sur-
faces and has minimal vascularity, particularly in the model
used in this study, a primary vascular response is probably
not relevant and cannot be responsible for the lower CMA-
induced phototoxicity.
The apparent high preferential localisation of CMA in
tumours would not have been anticipated from in vitro and
ex vivo experiments in which CMA showed no seective
cytotoxicity (Goff et al., 1991, 1992). The reasons for this
observation are not obvious. The tumour cells being analysed
in this study are asctic and are either single-cell suspensions
or clumps of cells. As such, the neovasculature and the
lymphatic systems are probably not well developed and are
therefore unlikely to be responsible for the preferential
tumour retention. It is possible that preassociation with
physiological macromolcular components in vivo causes this
differential (Kongshaug et al., 1989). Alternatively, the ex-
tacted species that is being interpreted as CMA from fluo-
rescence data is a metabolite with similar optical proper-
ties.
Comparison of in vivo and in vitro photodestruction reveals
that in vivo PDT is inefficient compared with in vitro, prob-
ably because light delivery is more effective in vitro. For
similar intracellular photosensitiser content (-2 fmol percell)
and incident fluence, virtually a 100% cytotoxicity was ob-
served for in vitro irradiations (Goff et al., 1991). These data
also suggest a dominant cellular mechanism since no in-
creased phototoxicity is observed in vivo, as is the case for
sensitisers with a strong vascular component (Henderson &
Dougherty, 1992).
In summary, our experiments show that OC125 photoim-
munoconjugates administered intraperitoneally may be useful
in the palliative PDT of ovarian carcinoma. Because ovarian
cancer is predominantly a disease with serosal spread limited
to the peritoneal cavity, it is ideally suited for photo-
chemotherapy. The peritoneal surface can be exposed to laser
irradiation both intraoperatively and during laparoscopy.
Small residual disease following cytoreductive surgery, micro-
scopic disease or diaphragmatic studding could readily be
treated by this modality.
Our study suggests that for optimal tumoricidal effect,
PDT may need to be administered in multiple treatments.
This is similar to the results of Tochner et al. (1985, 1986),
who used haematoporphyrin-based PDT to treat a murine
ovarian cancer model. With a single treatment, even at high
sensitiser and light doses, approximately 50% of the tumour
cells survived. Multiple treatments administered intra-
peritoneally were significantly more effective at lower doses.
More quantitative light delivery and dosimetry are also
neceary to reduce phototoxic death seen in this study from
the generalised external irradiation of the peritoneal cavity.
There is also ample room for the improvement of tumour
uptake ofantibody-bound photosensitiser. The modest differ-
ential observed between tumour and non-tumour tisses with
the IC in this study is probably due to the inefficiency of
OC125. This antibody binds to some normal tisu (Niloff et
al., 1984; Miotti et al., 1987; Talbot et al., 1989) and the
antigen it binds to is also shed efficiently. The use of more
sPecific antibodies or antibody cocktails and/or fragments
should improve the efficacy of PDT. Chimeric antibodies
may further hanc uptake and reduce the human
anti-mouse antibody reponse cinically (Muto et al., 1990).
Aspects of the above issues are currently under investigation
in our laboratory.
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